Skip to main content
Equibles

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

Position in VRDN — Viridian Therapeutics, Inc.\DE

CIK 1164508 BOSTON, MA
Back to VRDN Full portfolio

Position in VRDN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$20,435,026
+$19,979,689 QoQ
Shares Held
1,112,413
+4678.6% QoQ
Ownership
0.982%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#32
of 215 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VRDN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,515,799,583 across 71 Biotechnology names. VRDN ranks #24 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 738,378 $366,774,503
2 INCY
Incyte Corp
 2,744,958 $311,168,438
3 REGN
Regeneron Pharmaceuticals, Inc.
 393,685 $245,478,344
4 EXEL
Exelixis, Inc.
 4,365,926 $237,550,033
5 GMAB
Genmab A/S
 4,975,324 $136,672,150
6 RPRX
Royalty Pharma plc
 2,435,341 $136,549,569
7 HALO
Halozyme Therapeutics, Inc.
 1,704,623 $133,420,842
8 ONC
BeOne Medicines Ltd.
 249,758 $71,173,537

All Filings in VRDN

Export CSV
3 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $20,435,026 1,112,413
2026-03-31 $455,337 23,279
2025-12-31 $10,619,948 341,258